About Surrozen, Inc.
http://www.surrozen.comSurrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration.
CEO
Craig C. Parker
Compensation Summary
(Year 2024)
Salary $605,000
Option Awards $627,710
Incentive Plan Pay $287,375
Total Compensation $1,520,085
Industry Biotechnology
Sector Healthcare
Went public August 10, 2021
Method of going public SPAC
Full time employees 40
Ratings Snapshot
Rating : B-
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 2
Price To Earnings 1
Price To Book 5
Overall Score 3
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
CONSONANCE CAPITAL MANAGEMENT LP
Shares:1.17M
Value:$24.25K
BAKER BROS. ADVISORS LP
Shares:833.33K
Value:$17.33K
LMR PARTNERS LLP
Shares:648.28K
Value:$13.48K
Summary
% Of Shares Owned 53.49%
Total Number Of Holders 21
Showing Top 3 of 21
Market Cap $188573
52w High $0.03
52w Low $0.01
P/E 0
Volume 6.65K
Outstanding Shares 8.57M
About Surrozen, Inc.
http://www.surrozen.comSurrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $983K | $11.87M ▲ | $-71.64M ▼ | -7.29K% ▼ | $-8.36 ▼ | $-71.58M ▼ |
| Q2-2025 | $983K | $10M ▼ | $39.75M ▲ | 4.04K% ▲ | $2.55 ▲ | $-8.88M ▲ |
| Q1-2025 | $983K ▲ | $10.53M ▲ | $-26.97M ▲ | -2.74K% ▲ | $-7.43 ▲ | $-9.26M ▼ |
| Q4-2024 | $655K ▼ | $9.25M ▲ | $-28.04M ▼ | -4.28K% ▼ | $-9 ▼ | $-8.27M ▼ |
| Q3-2024 | $10M | $8.77M | $-1.43M | -14.34% | $-0.44 | $1.57M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $81.33M ▼ | $94.05M ▼ | $117.56M ▲ | $-23.52M ▼ |
| Q2-2025 | $90.39M ▼ | $102.7M ▼ | $55.58M ▼ | $47.11M ▲ |
| Q1-2025 | $101.64M ▲ | $114.83M ▲ | $109.16M ▲ | $5.67M ▲ |
| Q4-2024 | $34.56M ▲ | $48.47M ▲ | $69.85M ▲ | $-21.38M ▼ |
| Q3-2024 | $31.01M | $48M | $42.33M | $5.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-71.64M ▼ | $-9.04M ▼ | $-24K ▼ | $9K ▲ | $-9.05M ▲ | $-9.06M ▼ |
| Q2-2025 | $39.75M ▲ | $-6.11M ▲ | $-18K ▲ | $-5.12M ▼ | $-11.26M ▼ | $-6.13M ▲ |
| Q1-2025 | $-26.97M ▲ | $-9.28M ▼ | $-27K ▼ | $76.39M ▲ | $67.08M ▲ | $-9.31M ▼ |
| Q4-2024 | $-28.04M ▼ | $3.48M ▲ | $-19K ▼ | $91K ▲ | $3.55M ▲ | $3.46M ▲ |
| Q3-2024 | $-1.43M | $-6.75M | $0 | $-1K | $-6.75M | $-6.75M |
Revenue by Products
| Product | Q3-2025 |
|---|---|
 Collaboration and license revenue | $0 ▲ |
Revenue by Geography
| Region | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|
 UNITED STATES | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Craig C. Parker
Compensation Summary
(Year 2024)
Salary $605,000
Option Awards $627,710
Incentive Plan Pay $287,375
Total Compensation $1,520,085
Industry Biotechnology
Sector Healthcare
Went public August 10, 2021
Method of going public SPAC
Full time employees 40
Ratings Snapshot
Rating : B-
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 2
Price To Earnings 1
Price To Book 5
Overall Score 3
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Institutional Ownership
CONSONANCE CAPITAL MANAGEMENT LP
Shares:1.17M
Value:$24.25K
BAKER BROS. ADVISORS LP
Shares:833.33K
Value:$17.33K
LMR PARTNERS LLP
Shares:648.28K
Value:$13.48K
Summary
% Of Shares Owned 53.49%
Total Number Of Holders 21
Showing Top 3 of 21